Abstract
Objective To establish a method to assess risks associated with preimplantation genetic testing (PGT) in embryos simultaneously with adhered sperm and cumulus cells.
Design A prospective pilot study.
Setting University teaching hospital.
Patient(s) 120 frozen blastocysts that could be biopsied from 34 patients who had experienced repeated implantation failure or abortion due to chromosomal abnormalities after embryos transfer in prior routine IVF cycles.
Intervention(s) Chromosome screening and parental DNA contamination testing was performed in the surplus frozen IVF blastocysts from 34 patients.
Main Outcome Measure(s) Parental DNA contamination rate and euploidy rate in biopsied blastocysts.
Result(s) A new quantification method for parental contamination testing (qPCT) in single-cell whole-genome amplification (WGA) products based on allelic ratio analysis was established and validated in an artificial model by comparing 22 results obtained before and after adding different numbers of sperm and cumulus cells to biopsied TE cells. The results of the prospective clinical study of qPCT-PGT-A showed that the maternal contamination rate was 0.83% (1/120) and the risk of paternal contamination was negligible. The euploidy rate in these blastocysts was 47.50% (57/120), and 21 frozen embryo transfer (FET) cycles resulted in ten ongoing clinical pregnancies and four healthy births.
Conclusion(s) The evidence we provide in the study shows a low risk of PGT in embryos simultaneously with adhered sperm and cumulus cells. The qPCT assay can be used to detect the risk of potential contamination and ensure the accuracy of PGT results, thereby improving the clinical outcome of IVF.
Capsule During PGT for human frozen conventional IVF embryos, paternal source pollution is negligible, while maternal pollution can not be ignored. qPCT method can effectively detect the parent DNA contamination in WGA products of biopsied TE cells.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by grants from the Science and Technology Program of Guangzhou (201704020217), the National Key Research and Development Program of China (2018YFC1002604) and the National Natural Science Foundation of China (81800184).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics Committee of Guangdong Women and Children Hospital gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Y.D., D.L., Y.Z. and C.W. should be considered similar in author order.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
